Member Info for PM2022

I would argue almost every paragraph is misleading therefore If I wanted I could write a novel. Don't have the time for that.

I have answered some of them. Oh and he keeps saying he will be back in July and will buy in the next placings or staff get added. The list just goes on.

If compounds were only valued when they get to market then everything would be valued at zero. Likes of Synairgen valued at 300 million for one phase 2 compound would zero, SAR without a deal would also have been zero and every other pharma. He knows all this. It's all misleading.

He also took something out of the Cenkos report the other week and was proven by everyone to lie because he knows people don't read it.

Anyway I have better things to do than spend the entire night writing long messages but just briefly.

In regards to the strategy to build the company it's a 3/5 year strategy and they have one already. They were looking to acquire the second acquisition in H1 but they have slightly modified the approach to build then buy after the votes. Regardless I did read somewhere it would only cost 0.5-1 million but not going to bother searching where. It just comes to mind. Therefore it's peanuts and would actually result in larger revenue and contracts. A3/A4 will likely be done years later once they have struck a deal so not concerned. Besides, placing at 40/50p for a few million is no real dilution and I would think the SP would get to that price at some point.

201 will get done IMO and with three world class pre-clinicals the company will not be valued at 5 million, plus a lab and potentially 201. That is wishful thinking. As I said they have flexibility if they need cash so they can wait until 201 is done even if it takes another 6 months. They have time and the SP will be higher even if they do have to raise later in the year. They should update us though or try and conclude before June.

In regards to voting you are not a holder therefore you don't have a say. It's the shareholders and will likely be dictated by where the SP is. Simple. You are only making it more likely that Suzy gets voted out because you are attempting to hold back the SP for your own personal agenda by misleading others.

DDDD- It just shows everyone you don't understand finances, placings and market caps. Therefore I don't think I would listen to you.

Your posts are all misleading to say the least. I have posted Adam's post regarding deals and payments backed with evidence.

Recent oncology dealmaking trends provide insights on strategies for dealmaking in the current market.

Early dealmaking appears to be the norm in oncology nowadays, as 73% of non-acquisition deals from 2015 to 2022 involved preclinical ventures.

Mean preclinical oncology acquisition deal – 359M; mean licensing deal – 540M; mean partnering deal – 985M (all USD). We have a MCap of 10M USD.

The mean deal values of partnering or licensing deals occurring at phase 1 were even lower than those occurring at the preclinical stage, though the upfront payments were slightly higher. Contrary to the common belief, the data suggest that oncology ventures don’t become a lot more valuable once they enter the clinic. No evidence was found for the necessity to clinically de-risk a platform technology. On the contrary, about half of the platform companies were still preclinical at the time of the deal.

Given the fierce competition in oncology nowadays, big pharma can no longer afford to sit on their hands waiting for the next-generation technology to be validated in the clinic.

Atlas have recognized this and developed a different business model for 24% of their portfolio companies, which is called the special purpose vehicle (SPV) or LLC holding company model. In these types of company structures, there is a holding company that has the platform IP and separate subsidiaries (each an SPV) for individual programs that contain target-specific IP. This model is ideal for platform companies and has been successfully used by companies such as Nimbus, F-star and Teneobio.

SPVs can leverage the full economic potential of a platform, but also create tremendous flexibility. A company could progress an SPV to a bigger value inflection point when it has capital available to do so, or alternatively, seek a risk- and resource-sharing partnership to reap more of the commercial benefits. This makes sense when capital from the private and public markets is readily available. Conversely, in cases of economic downturns, like the bear market we are facing right now, a company can focus resources on its mission-critical SPVs and seek licensing or acquisition deals for non-core SPVs.

So, it turns out the BOD are two years ahead of the curve on this. Credit where it is due.

https://www.nature.com/articles/d43747-023-00002-6

5p= 5 million market cap.

Put it this way, Barcelona SPV is almost a given here and further lab revenue updates are expected. As a result, it's highly unlikely a significant discount is offered. More chance of winning the lottery than 5/6p placing later in the year imo.

Most people have agendas here but Val has enough cash for the remainder of the year so has flexibility to get any placing done at much higher prices given the amount of news due as and when needed. Given the strong science and foundations in place it would get taken even with a 1p discount at these prices imo. Any potential drop in the share price would likely be taken by buyers who are eager to invest.

It's worth noting that the previous placing was carried out at the current market price at the time of 11p, without any discount. This occurred prior to Barcelona SPV if it happens as expected and a lab, which should increase the company's overall value which was already significantly undervalued.

If Porky really had money he would be buying now. He lost it all in DDDD and now is just keeping occupied. Maybe he has lots of personal issues , and as a result, spends all his time bashing a stock that he does not hold or likes and misleads people.

In regards to 201, the facts are LOI is still in place and as Suzy previously stated they were assisting with 301 patents. I would rather see 201 and 301 over the line than none of them as I see significant upside if these got over the line. In my opinion, there is a deadline for TRX, as it wouldn't be logical to continue past June if Suzy or Kevin were to lose their jobs. Therefore, they must either meet the deadline and complete the deal, or give a positive update by then. I am happy to wait until June and beyond, and it's possible that this timeframe will catch many people off guard.

The smart money is on a buy at 10p. Remember if everything failed and a placing came in July/ August we should still be 25/30p with what we have WITHOUT 201. Any placing would therefore get snapped up fast at these prices most likely by BOD, Stella and her contacts or institutional investors. Not to dreamers like Porky, who promised to buy in the last two placings, promised to buy when VAL was in the 20s and if it went to 10p and also promised to buy if additional staff were taken before Stella and Cathy joined. He is NOT buying as he has lost his money.

I agree with Adam's opinion 2p downside from here and unlimited upside therefore he is smart to be buying at these times. Dreamers keep dreaming. I am going for 25-50p by June. Barcelona news is due so take it or leave. I would ignore sentiment and buy as it changes fast with news but that is just me. DYOR.

I would have thought this would have been the best opportunity to withdraw LOI if they wanted but I think it's happening as they had an option but are still proceeding so progress must be excellent or at a late stage. I would assume they are also helping with 301 patents as well. You would think everyone is working to get it done before June. Lots of news to come including Barcelona and lab contracts.

CLX001 is a peptide that is intended to be delivered in a nanoformulation. While the nanoformulation is undergoing further optimisation, the unformulated peptide continues to undergo biological testing. Safety screen data generated in Q1 2023 confirms no immediate toxicology concerns. Regulatory planning activities have also been commenced.

CLX001 has a fantastic chance of securing a huge preclinical deal with upfront payments of 10s million and milestone payments of 100s million. This can happen at any time. No immediate toxicology concerns. Barcelona to come. We should get some big investment coming through in the coming weeks to take us right up where we should be. Easy multimagger.

Great posts from Adam.

Barcelona news on the way and it looks positive. Given our current price we could double that alone.
We now have.
CLX001
301
lab
201
Barcelona news to come shortly.

All for 10 million. No question we should be 30p plus with lots of news to come and we should have no downside here at these prices.

301 moving into formal preclinical studies. No cure for Endometriosis. Each SPV is worth at least 10 million and Barcelona looks highly likely. We already have CLX. We should double with Barcelona news imo so if that is happening a great buy at these prices.

At 10 million market cap we should at least be 25/30p. The lab is progressing well.

It's funny as soon as you sell you open your big mouth attempting the same boring discrediting posts to suit your agenda. If you broke even then good for you. I can wait until the news when you will be jumping in at 20 p plus.

You buy a few k max and sell with a loss or when you break even. Looking back at your post yesterday says it all. Almost breaking even. It appears that you only buy to break even and then again. Complete loser. Twist it how you want but you have made jack chit here.

Not relevant PORKY. Tomorrow or next week who cares. What we do know is that Barcelona is due very soon as the deadline expired in February. FACT.

While it's not catastrophic, shareholders do require some clarity and updates after waiting for a considerable amount of time. It appears that there may have been some missteps in the strategy to maintain the share price. Hopefully, improvements will be made going forward.

It might be worth considering a change in advisors, as they don't seem to be prioritizing the company's share price.

It's a bit like VAL burning 25 million a year with a market cap of 10 million. How will they ever do a placing to cover the costs if the market cap is so much lower than what they are burning. Anyway good luck just my thoughts only and I am probably wrong so don't listen to me.

Val is ok as only burning 2/3 million a year and market cap should significantly increase with the number of pending outcomes. Nobody can predict when so we just have to wait.

10p for Osirium my ****. 1.92 market cap but operating loss of 3.36 million plus debt 0.7 million. Personally I would never invest in a stock that has higher operating loss than cash and market cap. 90:10 for it to go bust imo unless they make a huge profit and increase that market cap significantly.

Anyway this is a VAL board. Hopefully we get news this week.

Those selling here will most likely never make money on this stock. 10 million market cap and about 4/5 decent outcomes due most likely before June. Each one is probably worth more than our market cap alone. Extra incentive to do well due to the votes in June.

201 plus 301 plus Barcelona plus Hakkaido vs no outcomes before June = 8/9p or likely 60/70p or anything between these levels with some outcomes.

Suzy was confident of progress on the legacy assets and evaluation projects so it's almost guaranteed we get some decent news at some point.

The great part is that they have lots to prove before June at such a low price. Suzy has been speaking positively about 301 for the last 3 years and 201 she has always been very confident.

Naturally you would expect them to work towards a target date and I sure they will get news out before June for both 201 and 301. Remember TRX knows if Suzy is voted out then it's potentially three years worth of work wasted so I think 201 will get done very soon or at least a positive update.

Barcelona, Hakkaido, 201, 301, lab updates all very likely before June. Stella knows how to create momentum which will be lots of news in a short space of time from now to June and we shall where we are but a great buy at these prices.

Porky you contradict yourself to fit your agenda. You were the one shouting 150p last year. Forget TRX, VAl has progressed much further and you are only here because you are in love with the stock. Love at first sight and you can't let go.

It might be time to consider other investment opportunities if you do not see value in the current stock Porky. Dwelling on the possibility of a significant drop to zero may not be productive, and it may be more beneficial to face the reality of the current situation. If you are not currently invested and have been following the board for two years, it may be worth considering exploring other options.

Phimx,

201 Results speak for themselves and were done at lower dosages. It was excellent. Adam went through this already if you had been following the last two years. Big pharma doesn't have the patent experts to reformulate the drug. TRX has these skills. As for funding we shall see but no point speculating. It's still progressing and when it's done then we will not open anywhere near 10p.

The point is we are valued at 10 million only. Therefore even CLX is probably worth more than double our current market cap. We have a number of pending outcomes which could double us on their own. It's all relative to the market cap. You don't get valued at zero if you don't have a deal just yet. Potential is always factored in.

VAL301 -Endometriosis no cure or effective treatment. Hint of success will add huge value. Affects about 10% women.

CLX001- Triple negative breast cancer. Very hard to treat.New treatments in very high demand.

VAL201- Prostate cancer. A big one for older men again treats late stage prostate cancer which is very hard to treat.

Not to mention Hakkaido or Barcelona just yet. That would suggest the treatments are in high demand and any hint of success will rocket the SP. All for 10 million. Can't go wrong.

Phimx,

What brings you to this great board and not to other ones? Eyeing up an investment or are you here to warn us all?

Phimx,

201 is not priced in. The bottom line is we have to wait and see what happens. It has great potential but patents need sorting out and TRX have the skills to do that unlike most other partners.

Anyway we wait and see. Not much to discuss about 201. Barcelona and CLX is what you need to focus on if you are interested otherwise wait for 201 news imo.